{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T17:19:50Z","timestamp":1794590390566,"version":"4.9.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,3,17]],"date-time":"2023-03-17T00:00:00Z","timestamp":1679011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,17]],"date-time":"2023-03-17T00:00:00Z","timestamp":1679011200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Advanced intrahepatic cholangiocarcinoma (ICC) has a dismal prognosis. Here, we report the efficacy and safety of combining toripalimab, lenvatinib, and gemcitabine plus oxaliplatin (GEMOX) as first-line therapy for advanced ICC. Thirty patients with pathologically confirmed advanced ICC received intravenous gemcitabine (1\u2009g\/m\n                    <jats:sup>2<\/jats:sup>\n                    ) on Days 1 and 8 and oxaliplatin (85\u2009mg\/m\n                    <jats:sup>2<\/jats:sup>\n                    ) Q3W for six cycles along with intravenous toripalimab (240\u2009mg) Q3W and oral lenvatinib (8\u2009mg) once daily for one year. The expression of programmed death-ligand 1 (PD-L1) and genetic status was investigated in paraffin-embedded tissues using immunohistochemistry and whole-exome sequencing (WES) analysis. The primary endpoint was the objective response rate (ORR). Secondary outcomes included safety, overall survival (OS), progression-free survival (PFS), disease control rate (DCR) and duration of response (DoR). As of July 1, 2022, the median follow-up time was 23.5 months, and the ORR was 80%. Twenty-three patients achieved partial response, and one achieved complete response. Patients (21\/30) with DNA damage response (DDR)-related gene mutations showed a higher ORR, while patients (14\/30) with tumor area positivity \u22651 (PD-L1 staining) showed a trend of high ORR, but without significant difference. The median OS, PFS, and DoR were 22.5, 10.2, and 11.0 months, respectively. The DCR was 93.3%. Further, 56.7% of patients experienced manageable grade \u22653 adverse events (AEs), commonly neutropenia (40.0%) and leukocytopenia (23.3%). In conclusion, toripalimab plus lenvatinib and GEMOX are promising first-line regimens for the treatment of advanced ICC. A phase-III, multicenter, double-blinded, randomized study to validate our findings was approved by the National Medical Products Administration (NMPA, No. 2021LP01825).\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Trial registration Clinical trials<\/jats:bold>\n                    : NCT03951597.\n                  <\/jats:p>","DOI":"10.1038\/s41392-023-01317-7","type":"journal-article","created":{"date-parts":[[2023,3,26]],"date-time":"2023-03-26T15:56:08Z","timestamp":1679846168000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":159,"title":["Toripalimab combined with lenvatinib and GEMOX is a promising regimen as first-line treatment for advanced intrahepatic cholangiocarcinoma: a single-center, single-arm, phase 2 study"],"prefix":"10.1038","volume":"8","author":[{"given":"Guo-Ming","family":"Shi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Yong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-Chuan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guo-Huan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Cheng","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xian-Long","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin-Ying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8310-1880","authenticated-orcid":false,"given":"Lei","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning-Ling","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Wu","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang-Jian","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2716-9338","authenticated-orcid":false,"given":"Xin-Rong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Feng","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng-Gang","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5158-629X","authenticated-orcid":false,"given":"Jia","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2118-1117","authenticated-orcid":false,"given":"Jian","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,17]]},"reference":[{"key":"1317_CR1","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/S0140-6736(21)00153-7","volume":"397","author":"JW Valle","year":"2021","unstructured":"Valle, J. W., Kelley, R. K., Nervi, B., Oh, D. Y. & Zhu, A. X. Biliary tract cancer. Lancet 397, 428\u2013444 (2021).","journal-title":"Lancet"},{"key":"1317_CR2","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/S2468-1253(22)00043-7","volume":"7","author":"DY Oh","year":"2022","unstructured":"Oh, D. Y. et al. Gemcitabine and cisplatin plus durvalumab with or without tremelimumab in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, single-centre, phase 2 study. Lancet Gastroenterol. Hepatol. 7, 522\u2013532 (2022).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"1317_CR3","doi-asserted-by":"publisher","first-page":"298","DOI":"10.5009\/gnl.2009.3.4.298","volume":"3","author":"J Park","year":"2009","unstructured":"Park, J. et al. Natural history and prognostic factors of advanced cholangiocarcinoma without surgery, chemotherapy, or radiotherapy: a large-scale observational study. Gut Liver 3, 298\u2013305 (2009).","journal-title":"Gut Liver"},{"key":"1317_CR4","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","volume":"362","author":"J Valle","year":"2010","unstructured":"Valle, J. et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N. Engl. J. Med. 362, 1273\u20131281 (2010).","journal-title":"N. Engl. J. Med."},{"key":"1317_CR5","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1002\/cam4.299","volume":"3","author":"F Fiteni","year":"2014","unstructured":"Fiteni, F. et al. Cisplatin\/gemcitabine or oxaliplatin\/gemcitabine in the treatment of advanced biliary tract cancer: a systematic review. Cancer Med. 3, 1502\u20131511 (2014).","journal-title":"Cancer Med."},{"key":"1317_CR6","doi-asserted-by":"publisher","unstructured":"Dimitrios, M. et al. Advances in the treatment of intrahepatic cholangiocarcinoma: an overview of the current and future therapeutic landscape for clinicians. CA Cancer J. Clin. https:\/\/doi.org\/10.3322\/caac.21759 (2022).","DOI":"10.3322\/caac.21759"},{"key":"1317_CR7","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/s41571-021-00552-7","volume":"19","author":"L Kraehenbuehl","year":"2021","unstructured":"Kraehenbuehl, L., Weng, C. H., Eghbali, S., Wolchok, J. D. & Merghoub, T. Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways. Nat. Rev. Clin. Oncol. 19, 37\u201350 (2021).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1317_CR8","doi-asserted-by":"publisher","first-page":"EVIDoa2200015","DOI":"10.1056\/EVIDoa2200015","volume":"1","author":"D-Y Oh","year":"2022","unstructured":"Oh, D.-Y. et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evid. 1, EVIDoa2200015 (2022).","journal-title":"NEJM Evid."},{"key":"1317_CR9","doi-asserted-by":"publisher","first-page":"497","DOI":"10.21037\/apm.2020.03.14","volume":"9","author":"J Liu","year":"2020","unstructured":"Liu, J., Wang, C., Cao, L. & Li, S. Treatment of advanced intrahepatic cholangiocarcinoma with sintilimab combined with tegafur-gimeracil-oteracil potassium capsules (S-1): a case report. Ann. Palliat. Med. 9, 497\u2013503 (2020).","journal-title":"Ann. Palliat. Med."},{"key":"1317_CR10","doi-asserted-by":"publisher","first-page":"368","DOI":"10.3389\/fmed.2020.00368","volume":"7","author":"ZL Liu","year":"2020","unstructured":"Liu, Z. L. et al. Anti-PD-1 immunotherapy and radiotherapy for stage IV intrahepatic cholangiocarcinoma: a case report. Front. Med. 7, 368 (2020).","journal-title":"Front. Med."},{"key":"1317_CR11","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1186\/s40425-019-0692-z","volume":"7","author":"X Liu","year":"2019","unstructured":"Liu, X. et al. Local and abscopal responses in advanced intrahepatic cholangiocarcinoma with low TMB, MSS, pMMR and negative PD-L1 expression following combined therapy of SBRT with PD-1 blockade. J. Immunother. Cancer 7, 204 (2019).","journal-title":"J. Immunother. Cancer"},{"key":"1317_CR12","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1186\/s12957-020-02082-5","volume":"18","author":"L Tian","year":"2020","unstructured":"Tian, L. et al. PD-1\/PD-L1 expression profiles within intrahepatic cholangiocarcinoma predict clinical outcome. World J. Surg. Oncol. 18, 303 (2020).","journal-title":"World J. Surg. Oncol."},{"key":"1317_CR13","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1158\/1078-0432.CCR-15-0715","volume":"22","author":"F Sabbatino","year":"2016","unstructured":"Sabbatino, F. et al. PD-L1 and HLA class I antigen expression and clinical course of the disease in intrahepatic cholangiocarcinoma. Clin. Cancer Res. 22, 470\u2013478 (2016).","journal-title":"Clin. Cancer Res."},{"key":"1317_CR14","doi-asserted-by":"publisher","first-page":"4678","DOI":"10.7150\/thno.36276","volume":"9","author":"JC Lu","year":"2019","unstructured":"Lu, J. C. et al. Distinct PD-L1\/PD1 profiles and clinical implications in intrahepatic cholangiocarcinoma patients with different risk factors. Theranostics 9, 4678\u20134687 (2019).","journal-title":"Theranostics"},{"key":"1317_CR15","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1097\/00007890-199809150-00008","volume":"66","author":"O Abbasoglu","year":"1998","unstructured":"Abbasoglu, O. et al. Does intraoperative hepatic artery flow predict arterial complications after liver transplantation? Transplantation 66, 598\u2013601 (1998).","journal-title":"Transplantation"},{"key":"1317_CR16","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1038\/aps.2016.161","volume":"38","author":"J Fu","year":"2017","unstructured":"Fu, J. et al. Preclinical evaluation of the efficacy, pharmacokinetics and immunogenicity of JS-001, a programmed cell death protein-1 (PD-1) monoclonal antibody. Acta Pharm. Sin. 38, 710\u2013718 (2017).","journal-title":"Acta Pharm. Sin."},{"key":"1317_CR17","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s13045-018-0693-2","volume":"12","author":"B Tang","year":"2019","unstructured":"Tang, B. et al. Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patients. J. Hematol. Oncol. 12, 7 (2019).","journal-title":"J. Hematol. Oncol."},{"key":"1317_CR18","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s40265-019-01076-2","volume":"79","author":"SJ Keam","year":"2019","unstructured":"Keam, S. J. Toripalimab: first global approval. Drugs 79, 573\u2013578 (2019).","journal-title":"Drugs"},{"key":"1317_CR19","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1093\/annonc\/mdz197","volume":"30","author":"F Wang","year":"2019","unstructured":"Wang, F. et al. Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib\/II clinical trial NCT02915432. Ann. Oncol. 30, 1479\u20131486 (2019).","journal-title":"Ann. Oncol."},{"key":"1317_CR20","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1038\/sj.bjc.6604129","volume":"98","author":"D Yoshikawa","year":"2008","unstructured":"Yoshikawa, D. et al. Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma. Br. J. Cancer 98, 418\u2013425 (2008).","journal-title":"Br. J. Cancer"},{"key":"1317_CR21","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1200\/JCO.2017.75.5009","volume":"36","author":"M Javle","year":"2018","unstructured":"Javle, M. et al. Phase II study of BGJ398 in patients with FGFR-altered advanced cholangiocarcinoma. J. Clin. Oncol. 36, 276\u2013282 (2018).","journal-title":"J. Clin. Oncol."},{"key":"1317_CR22","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.cca.2018.06.032","volume":"485","author":"MJ Qiu","year":"2018","unstructured":"Qiu, M. J. et al. Effects of liver-targeted drugs on expression of immune-related proteins in hepatocellular carcinoma cells. Clin. Chim. Acta 485, 103\u2013105 (2018).","journal-title":"Clin. Chim. Acta"},{"key":"1317_CR23","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1200\/JCO.19.01598","volume":"38","author":"MH Taylor","year":"2020","unstructured":"Taylor, M. H. et al. Phase IB\/II trial of lenvatinib plus pembrolizumab in patients with advanced renal cell carcinoma, endometrial cancer, and other selected advanced solid tumors. J. Clin. Oncol. 38, 1154\u20131163 (2020).","journal-title":"J. Clin. Oncol."},{"key":"1317_CR24","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/S2468-1253(19)30086-X","volume":"4","author":"M Ueno","year":"2019","unstructured":"Ueno, M. et al. Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study. Lancet Gastroenterol. Hepatol. 4, 611\u2013621 (2019).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"1317_CR25","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1093\/annonc\/mdy232","volume":"29","author":"AR Hansen","year":"2018","unstructured":"Hansen, A. R. et al. Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study. Ann. Oncol. 29, 1807\u20131813 (2018).","journal-title":"Ann. Oncol."},{"key":"1317_CR26","doi-asserted-by":"publisher","first-page":"4079","DOI":"10.1200\/JCO.2019.37.15_suppl.4079","volume":"37","author":"Y-J Bang","year":"2019","unstructured":"Bang, Y.-J. et al. Pembrolizumab (pembro) for advanced biliary adenocarcinoma: results from the KEYNOTE-028 (KN028) and KEYNOTE-158 (KN158) basket studies. J. Clin. Oncol. 37, 4079\u20134079 (2019).","journal-title":"J. Clin. Oncol."},{"key":"1317_CR27","unstructured":"Kemp, A. Imfinzi plus Chemotherapy Significantly Improved Overall Survival in 1st-line Advanced Biliary Tract Cancer in Topaz-1 Phase Iii Trial at Interim Analysis. https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2021\/imfinzi-improved-survival-in-biliary-tract-cancer.html (2021)."},{"key":"1317_CR28","first-page":"200","volume":"112","author":"A Lamarca","year":"2020","unstructured":"Lamarca, A. et al. Advanced intrahepatic cholangiocarcinoma: post hoc analysis of the ABC-01, -02, and -03 clinical trials. J. Natl Cancer Inst. 112, 200\u2013210 (2020).","journal-title":"J. Natl Cancer Inst."},{"key":"1317_CR29","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1016\/j.annonc.2020.08.2271","volume":"31","author":"Z Lwin","year":"2020","unstructured":"Lwin, Z. et al. LBA41 LEAP-005: Phase II study of lenvatinib (len) plus pembrolizumab (pembro) in patients (pts) with previously treated advanced solid tumours. Ann. Oncol. 31, 2271 (2020).","journal-title":"Ann. Oncol."},{"key":"1317_CR30","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1200\/JCO.2018.36.4_suppl.500","volume":"36","author":"J Lin","year":"2018","unstructured":"Lin, J. et al. Lenvatinib plus checkpoint inhibitors in patients (pts) with advanced intrahepatic cholangiocarcinoma (ICC): preliminary data and correlation with next-generation sequencing. J. Clin. Oncol. 36, 500\u2013500 (2018).","journal-title":"J. Clin. Oncol."},{"key":"1317_CR31","doi-asserted-by":"publisher","first-page":"4099","DOI":"10.1200\/JCO.2021.39.15_suppl.4099","volume":"39","author":"Z Jian","year":"2021","unstructured":"Jian, Z. et al. Lenvatinib plus toripalimab as first-line treatment for advanced intrahepatic cholangiocarcinoma: a single-arm, phase 2 trial. J. Clin. Oncol. 39, 4099\u20134099 (2021).","journal-title":"J. Clin. Oncol."},{"key":"1317_CR32","doi-asserted-by":"publisher","first-page":"e16163","DOI":"10.1200\/JCO.2021.39.15_suppl.e16163","volume":"39","author":"G-M Shi","year":"2021","unstructured":"Shi, G.-M. et al. Phase II study of lenvatinib in combination with GEMOX chemotherapy for advanced intrahepatic cholangiocarcinoma. J. Clin. Oncol. 39, e16163\u2013e16163 (2021).","journal-title":"J. Clin. Oncol."},{"key":"1317_CR33","doi-asserted-by":"publisher","first-page":"e001240","DOI":"10.1136\/jitc-2020-001240","volume":"8","author":"X Chen","year":"2020","unstructured":"Chen, X. et al. Camrelizumab plus gemcitabine and oxaliplatin (GEMOX) in patients with advanced biliary tract cancer: a single-arm, open-label, phase II trial. J. Immunother. Cancer 8, e001240 (2020).","journal-title":"J. Immunother. Cancer"},{"key":"1317_CR34","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1038\/s41591-021-01444-0","volume":"27","author":"HQ Mai","year":"2021","unstructured":"Mai, H. Q. et al. Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial. Nat. Med. 27, 1536\u20131543 (2021).","journal-title":"Nat. Med."},{"key":"1317_CR35","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/s41571-018-0114-z","volume":"16","author":"PG Pilie","year":"2019","unstructured":"Pilie, P. G., Tang, C., Mills, G. B. & Yap, T. A. State-of-the-art strategies for targeting the DNA damage response in cancer. Nat. Rev. Clin. Oncol. 16, 81\u2013104 (2019).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1317_CR36","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1002\/mco2.103","volume":"2","author":"M Wang","year":"2021","unstructured":"Wang, M., Chen, S. & Ao, D. Targeting DNA repair pathway in cancer: mechanisms and clinical application. MedComm (2020) 2, 654\u2013691 (2021).","journal-title":"MedComm (2020)"},{"key":"1317_CR37","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1038\/nature08250","volume":"461","author":"SB Ng","year":"2009","unstructured":"Ng, S. B. et al. Targeted capture and massively parallel sequencing of 12 human exomes. Nature 461, 272\u2013276 (2009).","journal-title":"Nature"}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-023-01317-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-023-01317-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-023-01317-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T21:18:38Z","timestamp":1729113518000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-023-01317-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,17]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1317"],"URL":"https:\/\/doi.org\/10.1038\/s41392-023-01317-7","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,17]]},"assertion":[{"value":"11 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"106"}}